A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 6, 2010, Pages 517-531

  Kipnes, M S ^a   Hollander, P ^b   Fujioka, K ^c   Gantz, I ^d   Seck, T ^d   Erondu, N ^d   Shentu, Y ^d   Lu, K ^d   Suryawanshi, S ^d   Chou, M ^d   Johnson Levonas, A O ^d   Heymsfield, S B ^d   Shapiro, D ^d   Kaufman, K D ^d   Amatruda, J M ^d  

^a Cetero Research   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c SCRIPPS CLINIC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cannabinoid 1 receptor; Diabetes; Endocannabinoid; Obesity; Randomized clinical trial

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TARANABANT; TRIACYLGLYCEROL;

ADULT; AGED; AGEUSIA; AGGRESSION; AMNESIA; ANGER; ANHEDONIA; ANOSMIA; ANXIETY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ATTENTION DISTURBANCE; BACKACHE; BALANCE DISORDER; BLINDNESS; BLURRED VISION; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BURNING SENSATION; CALORIC RESTRICTION; CEREBELLAR ATAXIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CLONUS; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COORDINATION DISORDER; DEMENTIA; DEPRESSION; DIARRHEA; DIPLOPIA; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSGEUSIA; DYSTHYMIA; EPILEPSY; EXERCISE; FACIAL NERVE PARALYSIS; FEMALE; FLUSHING; FORMICATION; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART RATE; HEMIPARESIS; HEMIPLEGIA; HOT FLUSH; HUMAN; HYPERESTHESIA; HYPERHIDROSIS; HYPERREFLEXIA; HYPESTHESIA; HYPOGEUSIA; INSULIN SENSITIVITY; INTESTINAL DYSMOTILITY; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDIASTINUM DISEASE; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MERALGIA PARESTHETICA; METABOLIC DISORDER; MIGRAINE; MIGRAINE WITH AURA; MOOD DISORDER; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; NEURALGIA; NEURITIS; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; NYSTAGMUS; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PANIC; PARESTHESIA; PATHOLOGICAL CRYING; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; POSITIONAL DIZZINESS; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SCOTOMA; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYNCOPE; TENSION HEADACHE; THORAX DISEASE; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; TREMOR; UNCONSCIOUSNESS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 77952290508     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01188.x     Document Type: Article

References (54)

1. Diabetes Atlas 2003, 2nd edn, International Obesity Task Force
2. Eberhardt MS, Ogden C, Engelgau M, Caldwell B. Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002. MMWR, CDC Surveill Summ 2004 53:1066-1068.
3. Prentice AM, Jebb SA. Beyond body mass index. Obes Rev 2001, 2:141-147.
4. Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
5. Lindstrom J, Ilanne-Parikka P, Peltonen M. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
6. Pan XR, Li GW, Hu YH. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
7. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20:1744-1766.
8. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
9. Klein S, Sheard NF, Pi-Sunyer X. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004, 27:2067-2073.
10. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obesity Res 2004, 12(Suppl):151S-162S.
11. Li Z, Maglione M, Tu W. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532-546.
12. Cota D, Marsicano G, Tschop M. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
13. Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (Lond) 2006, 30((Suppl 1)):S33-S38.
14. Lin LS, Lanza TJ, Jewell JP. Discovery of N- [(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- [5-(trifluoromethyl)pyridin-2-yl]oxypropanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006, 49:7584-7587.
15. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
16. Addy C, Cote J, Li S. Taranbant plasma concentrations are increased when co-administered with ketoconazole or diltiazem. Obesity, Program Abstract Supplement 15 2007, A147. [September 2007],
17. Katz A, Nambi SS, Mather K. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
18. Keller SD, Bayliss MS, Ware JE, Hsu MA, Damiano AM, Goss TF. Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Health Serv Res 1997, 32:367-384.
19. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obesity Res 2001, 9:102-111.
20. Wechsler D. WAIS-III WMS-III Technical Manual 1997, San Antonia, TX, PsychCorp, Harcourt Brace & Co
21. McNair DM, Lorr M, Droppleman L. Manual for the Profile of Mood States (POMS) 1971, San Diego, CA, Educational and Industrial Testing Service
22. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999, 282:1737-1744.
23. Appendix 2: Request to Sponsors - Advice for the pharmaceutical industry in exploring their placebo-controlled clinical trials databases for suicidality and preparing data sets for analysis by FDA. 2006, 128-137. http://www.fdagov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf, Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Memorandum N.1.2. Overview for December Meeting of Psychopharmacologic Drug Advisory Committee (PDAC), Available at, Accessed 19 August 2009.
24. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007, 164:1035-1043.
25. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med 2005, 22:612-618.
26. Hollander PA, Elbein SC, Hirsch IB. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
27. Kelley DE, Bray GA, Pi-Sunyer FX. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002, 25:1033-1041.
28. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245-254.
29. Miles JM, Leiter L, Hollander P. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002, 25:1123-1128.
30. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004, 28:600-605.
31. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003, 26:125-131.
32. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004, 26:1427-1435.
33. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672. RIO-Diabetes Study Group.
34. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008, 31:2169-2176. SERENADE Study Group.
35. Aronne L, Tonstad S, Moreno M. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: high-dose study. Intern J Obesity 2009
36. Proietto J, Rissanen A, Harp JB. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Intern J Obesity 2009
37. Norris SL, Zhang X, Avenell A. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005, CD004095.
38. Klein S, Allison DB, Heymsfield SB. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 2007, 85:1197-1202.
39. Gallagher D, Kelley DE, Yim JE. Adipose tissue distribution is different in type 2 diabetes. Am J Clin Nutr 2009, 89:807-814.
40. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
41. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009, 73:608-614.
42. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005, 365:1363-1364.
43. Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes (Lond) 2009, 33:947-955.
44. Tonstad S. Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors? Nat Clin Pract Cardiovasc Med 2006, 3:364-365.
45. Addy C, Wright H, Van Laere K. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008, 7:68-78.
46. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
47. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
48. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
49. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008, 29:1761-1771.
50. Little AA, Edwards JL, Feldman EL. Diabetic neuropathies. Pract Neurol 2007, 7:82-92.
51. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24:1069-1078.
52. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 2002, 53:1053-1060.
53. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 2005, 19:113-122.
54. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000, 23:1556-1562.